Editor Profiles

Pharmaceutical Analysis Drug Applied Research Center Tabriz University of Medical Sciences-Iran

Igor Grachev, M.D., Ph.D. is a Neurologist, Psychiatrist, Neuroscientist, Drug Developer, Translational Medicine/POC, Clinical Development, Medical Affairs and Imaging expert with over 20 years of extensive Pharma industry, academic and CRO biomedical research experience who has had roles of increasing responsibility and scope at MGH/Harvard Medical School, SUNY Upstate Medical University, Schering-Plough, Sanofi-Aventis, Merck, BioClinica, Merck Sharp & Dohme Corp, GE Healthcare, and Novartis Consumer Health. All his industry roles have involved the application of imaging, biomarkers and clinical neuroscience to drug development. Dr. Grachev is a member of the Coalition Against Major Diseases (CAMD), QIBA DCE-MRI, FDG- and amyloid-PET steering committees of RSNA, ADNI and ADNI2, Society of Nuclear Medicine, International Society to Advance Alzheimer Research and Treatment and has written and co-authored over 100 clinical research scientific publications including chapters on imaging biomarkers/technologies in three books “Methods in Pain Research (CRC Press),” “Complex Regional Pain Syndrome (IASP Press)” and “Imaging in CNS Drug Development (Springer Science, NY),” and served as a Chair of Industry Scientific Advisory Board for Parkinson’s Progression Markers Initiative, Michael J. Fox Foundation. Research interest: Neurobiology of Neurodegenerative disorders (Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis), Insomnia (incl. PSG), OCD, Depression, Anxiety, Schizophrenia, ADHD, Migraine, Acute & Chronic Pain, Stroke and other indications. Expert in clinical biomarkers and the following Imaging modalities: PET, SPECT, and MRI (Gd-MRI, vMRI, fMRI, MRS, DCE-MRI).

Adriana Costa Bacelo has completed her PhD at the age of 42 years from National Institute of Infectious Diseases Evandro Chagas – Oswaldo Cruz Foundation. She is a Member of Nutrition Service of Oswaldo Cruz Foundation, Member of the Research Center for Micronutrients of Federal University of Rio de Janeiro and Member of Clinical Research Laboratory on Mycobacteria of Oswaldo Cruz Foundation.

Dr. Carolle-Laure KPOUMIE has worked as pediatric assistant physician in pediatric’s department of faculty of medicine in Cameroon, as clinical researcher methodology, scientific writing, public health, oncology, internal medicine and continued her career in pharmaceutical industries in France. She participates in many congress with studies made in hospitals on relevant cases in the framework Studies and clinical research. She became head of department, director, head of district where she continued her research, writing of treatment protocols in different departments for common pathologies encountered in her context, managing Epidemic crisis such as cholera, meningitis, avian influenza, yellow fever and organizes campaigns on infectious diseases ,HIV, cardiovascular diseases, family planning, research on severe malaria, malnutrition in Children and participates in studies on neonatal mortality in underdeveloped countries. She work on ADR in hospital following drug administration, pharmacovigilance, vaccinovigilance, biovigilance, materiovigilance in underdeveloped countries, articles, medical information and therapeutic safety, clinical trials, Post-marketing, and other’s studies.

Dr. Srdanovic is originally from Montenegro, and has lived in New York since the age of twelve. After graduating with a Bachelor of Science in biology and doing research at the Hospital for Special Surgery, she decided to pursue her interest in research even further by completing a PhD in pharmaceutical sciences. She has experience in topical and transdermal drug delivery/formulation development, as well as a clinical research in the realm of interventional cardiology. Having worked on numerous clinical trials in interventional cardiology, she gained a deeper understanding of the clinical implications of drug release kinetics from drug-eluting stents and drug-coated balloons, linking the knowledge in pharmaceutics to clinical outcomes.